Featured Publications

Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

Virtual poster released on Jan 6, 2022
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery

IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P252,
Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer

Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P240
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery

Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P254
Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine

Publications

Found 68 Results
Page 2 of 7

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…

Journal: Nature Biotechnology


Transparency and reproducibility in artificial intelligence

Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…

Journal: Nature


Clinical landscape of oncolytic virus research in 2020

Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…

Journal: Journal for ImmunoTherapy of Cancer


pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model

Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.

Journal: Cell Death & Disease


Structures of Endocrine-Disrupting Chemicals Determine Binding to and Activation of the Estrogen Receptor α and Androgen Receptor

Endocrine-disrupting chemicals (EDCs) can interact with nuclear receptors, including estrogen receptor α (ERα) and androgen receptor (AR), to affect the normal endocrine system function, causing severe symptoms. Limited studies queried…

Journal: Environmental Science and Technology


Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)

The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019…

Journal: Journal of Translational Medicine


Quantitative Structure–Activity Relationship Models for Predicting Inflammatory Potential of Metal Oxide Nanoparticles

Although substantial concerns about the inflammatory effects of engineered nanomaterial (ENM) have been raised, experimentally assessing toxicity of various ENMs is challenging and time-consuming. Alternatively, quantitative structure–activity relationship (QSAR) models…

Journal: Environmental Health Perspectives


Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…

Journal: Leukemia


Advances in Computational Toxicology – Methodologies and Applications in Regulatory Science

Excerpt from Chapter 1 – Computational Toxicology Promotes Regulatory Science: New tools have become available to researchers and regulators including genomics, transcriptomics, proteomics, machine learning, artificial intelligence, molecular dynamics, bioinformatics,…


Realizing the promise of computational prediction in toxicology applications

Toxicant screening is only as efficient and effective as the underlying methods. Unfortunately, chemical toxicity screening is predominated by slow, laborious, and costly methods some of which raise ethical concerns….


Page 2 of 7